Publications

Source: Pharma Field, February 2019 NICE recommends new treatment for adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Pierre Fabre welcomes the National Institute for Health…

Source: Pharmaceutical Technology, February 2019 Chinese Sino Pharmaceutical has announced that China’s National Medical Products Administration has approved its subsidiary Chia-Tai Tianqing Pharmaceutical’s anti-tumour drug lenalidomide for multiple melanoma. The…

Source: Fierce Pharma, February 2019 Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition from French pharma lab Pierre…

Source: Healio, February 2019 The FDA has granted an orphan drug designation to PV-10, Provectus BioPharmaceuticals’ ocular melanoma treatment candidate, according to a press release. Rose bengal disodium, also called PV-10,…